One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and LiberiaKey takeaways:IAVI's Lassa vaccine candidate rVSVΔG-LASV-GPC has an acceptable safety profile and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback